

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Armstrong, R. A. et al) Art Unit: 1614
Serial No.: 10/715,177) Examiner:
Conf. No.: 4041)
Filed: 11/17/2003
For: Combination Of A PDE4 Inhibitor And Tiotropium Or Derivative
Thereof For Treating Obstructive Airways And Other Inflammatory
Diseases
Docket No.: 1/1345

Office of Initial Patent Examination's
Customer Service Center
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

February 19, 2004

REQUEST FOR CORRECTION OF FILING RECEIPT

Sir:

The undersigned respectfully requests correction of the Filing Receipt for
Application Number 10/715,177, Confirmation No. 4041.

**Please correct the spelling of the first name of the first named applicant from
"Rolsin" to --Roisin--, as noted on the attached copy of the Official Filing Receipt.**

The undersigned hereby requests that the United States Patent and Trademark
Office correct its records accordingly and issue a corrected Filing Receipt.

Respectfully submitted,

Michael P. Morris


Michael P. Morris
Attorney for Applicant(s)
Reg. No. 34,513

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road, P.O. Box 368
Ridgefield, CT 06877
Tel: (203) 798-4868
Date: February 19, 2004

Certificate of Transmission under 37 CFR 1.8
I hereby certify that this correspondence is being
facsimile transmitted to the United States Patent
and Trademark Office on February 19, 2004

Michael P. Morris

Michael P. Morris, Reg. No. 34,513



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/715,177	11/17/2003	1614	1022	1/1345		34	2

CONFIRMATION NO. 4041

28501
 BOEHRINGER INGELHEIM CORPORATION
 900 RIDGEBURY ROAD
 P. O. BOX 368
 RIDGEFIELD, CT 06877

FILING RECEIPT



OC000000011896846

Date Mailed: 02/12/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Rolsin

Rolsin A. Armstrong, Mystic, CT;
 John W. Watson, Ledyard, CT;
 Michael Yeadon, Sandwich, UNITED KINGDOM;

Assignment For Published Patent Application

Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GERMANY;

Domestic Priority data as claimed by applicant

This application is a CON of PCT/EP02/05643 05/23/2002
 which claims benefit of 60/303,845 07/09/2001
 and claims benefit of 60/293,555 05/25/2001


Foreign Applications

If Required, Foreign Filing License Granted: 02/12/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No





Title

Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).